Cassava discloses potential unblinding in Phase 2b study; collaborator indicted by DOJ

FILANA THERAPEUTICS, INC.

DOJ indicted Dr. Wang for allegedly causing false statements to NIH about simufilam; company terminated his consulting.
Internal investigation found senior employee may have unblinded Dr. Wang to some Phase 2b participants before bioanalysis.
Reported Phase 2b CANTAB analysis excluded ~42% of subjects for episodic memory; results reflect smaller analysis set.
Phase 3 trials fully enrolled (~1,900 patients), remain blinded; independent firms will handle bioanalysis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.